Cellular determinants of raltegravir exposure
HIV infection remains a worldwide concern and new drug treatments are required to tackle drug resistance and to reduce drug-associated host toxicity. Raltegravir, a new anti-HIV drug which targets the HIV integrase enzyme, is now being used in anti-HIV treatment and has shown impressive efficacy and...
| Main Author: | |
|---|---|
| Published: |
University of Liverpool
2012
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.632138 |